Breaks Categories: News

WednesdayMay 17, 2017 9:49 am

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Presenting at 18th Annual B. Riley Co. Investor Conference on May 24

Internet advertising company SRAX (NASDAQ: SRAX) this morning announced plans to present at the 18th Annual B. Riley Co. Investor Conference, an invitation-only conference offering premier networking and business development opportunities with an attractive beachfront setting. The company’s presentation is scheduled to take place on Wednesday, May 24, 2017, at 3:25 p.m. PT at the newly-renovated Loews Santa Monica Beach Hotel in Santa Monica, California. In addition to the company’s presentation, SRAX CEO Christopher Miglino and CFO J.P. Hannan will be hosting one-on-one meetings with investors throughout the day. Interested parties should contact Kirsten Chapman at [email protected] or 415-433-3777 to…

Continue Reading

WednesdayMay 17, 2017 9:28 am

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Announces Treatment of First Patient in Phase 2 Trial of PRO 140 for Graft versus Host Disease

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the treatment of the first patient in its phase 2 clinical trial of PRO 140 for Graft versus Host Disease (GvHD), which represents its leading immunologic indication for the candidate. The multicenter, 60-patient study aims to evaluate the safety and efficacy of PRO 140 in treating GvHD, a potentially life-threatening complication affecting patients requiring a bone marrow transplant due to depleted immune systems. Currently, these transplant patients have just a 40-60% one-year survival rate, and relapsed GvHD is the leading cause of death. “We selected the transplantation indication called GvHD as…

Continue Reading

TuesdayMay 16, 2017 12:20 pm

NetworkNewsBreaks – Great Basin Scientific, Inc. (GBSN) Commences Commercial Launch of Bordetella Direct Test in U.S.; Receives CE Marking in EU

Great Basin Scientific (OTCQB: GBSN) this morning said it is initiating the U.S. commercial launch of its Bordetella Direct Test. The company also said it has received CE Marking designation under the European Directive on In Vitro Diagnostic Medical Devices, marking the company’s sixth assay to receive CE Marking under the directive. The Bordetella Direct Test also increases the company’s commercially available assays in the U.S. to five. “The processes we put in place that resulted in a swift FDA clearance also supported our ability to quickly commercialize the Bordetella Direct Test, much to the relief of many of our…

Continue Reading

TuesdayMay 16, 2017 12:18 pm

NetworkNewsBreaks – Mirna Therapeutics, Inc. (NASDAQ: MIRN) Shares Plummet On Merger Agreement with Synlogic

Shares of Mirna Therapeutics (NASDAQ: MIRN) dropped 23% after the company announced its definitive merger agreement with Synlogic, Inc. Per the agreement, Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company will focus on advancing Synlogic’s drug discovery and development platform for Synthetic Biotic medicines and operate under the Synlogic name. Synlogic also recently closed a $42 million Series C preferred stock financing from leading biotechnology investors to finance the merged company. “Following a thorough review of strategic alternatives, we are delighted to announce this transaction with Synlogic, which we believe is…

Continue Reading

TuesdayMay 16, 2017 12:14 pm

NetworkNewsBreaks – ChinaNet Online Holdings (NASDAQ: CNET) Trims Net Loss, Increases Revenues in Q1 2017

ChinaNet Online Holdings (NASDAQ: CNET) this morning reported a 43.6% YoY increase in first-quarter revenues, sending shares 12% higher in mid-morning trade. For the three months ended March 31, 2017, total revenues increased to $7.3 million from $5.1 million in the prior year. The increase is primarily due to sales of the company’s search engine marketing, which increased 252.1% to $5.0 million. Alternatively, revenues from Internet advertising and data services were $2.3 million, a decrease of 36.8% from $3.6 million in the first quarter of 2016. Gross profit for the first quarter of 2017 was $1.3 million compared to $1.6…

Continue Reading

TuesdayMay 16, 2017 10:37 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Craig Cheifetz, M.D. to Advisory Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. “I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies,” Ram Mukunda, CEO of IGC, stated in the news release. “We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions.” Cheifetz currently serves…

Continue Reading

MondayMay 15, 2017 4:27 pm

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Reports First Quarter 2017 Results, Management Reaffirms 2017 Guidance

Internet advertising company SRAX (NASDAQ: SRAX) today reported its first quarter 2017 financial results. Among the highlights, the company recorded quarterly revenue of $5.3 million with gross profit of $2 million. SRAX reported a net loss of $2 million for the three-month period, compared to a loss of $2.4 million in the first quarter of 2016. “Over the past year, we have expanded our offering, creating new high growth revenue streams like SRAX Reach, and established a leaner infrastructure,” Christopher Miglino, CEO and chairman of SRAX, stated in the news release. “While not evident in our first quarter financial results…

Continue Reading

FridayMay 12, 2017 12:58 pm

NetworkNewsBreaks – Capricor Therapeutics’ (NASDAQ: CAPR) ALLSTAR Trial Update Triggers Sell-off; Company to Focus on DMD, Trim Workforce

Shares of Capricor Therapeutics (NASDAQ: CAPR) dropped to a new 52-week low this morning – currently trading at $1.23 per share - after the company announced that six-month data of its ALLSTAR Trial demonstrated a low probability of achieving a statistically significant difference in its primary efficacy endpoint. "The lack of a clear difference in the change in scar size from baseline to six months between the active and control groups in the interim observations from ALLSTAR was unexpected. These results diverge from the consistent and extensive record of activity observed with our cell technology in the setting of cardiac…

Continue Reading

FridayMay 12, 2017 12:56 pm

NetworkNewsBreaks – Celsion Corporation (NASDAQ: CLSN) Shares Higher following Q1 Results, Development Program Update

Celsion Corporation (NASDAQ: CLSN) this morning posted its first-quarter results and issued an update on its lead program for ThemoDox®, currently in separate clinical trials for the treatment of primary liver cancer and recurrent chest wall breast cancer. Celsion’s immunotherapy program consists of GEN-1, currently in phase I development for the localized treatment of ovarian cancer. "Celsion continues to make major progress with respect to our ongoing global, pivotal Phase III OPTIMA Study in primary liver cancer.  This ground-breaking study continues to attract interest and support from the medical community, international regulatory agencies, and research organizations like the National Institutes…

Continue Reading

WednesdayMay 10, 2017 1:58 pm

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam

In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has…

Continue Reading